bms-1

BMS-1 (PD-1/PD-L1 inhibitor 1) is an inhibitor of the PD1-PD-L1 protein-protein interaction. It also acts as an immunomodulator. Programmed death ligand 1 (PD-L1) is a protein in humans that is encoded by the CD274 gene and the upregulation of PD-L1 allows Ys to evade the host immune system. High tumor expression of PD-L1 was associated with increased tumor aggressiveness and a 4.5-fold increased risk of death.

BMS-1166-n-piperidine-co-n-piperazine dihydrochloride, a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor, inhibits the PD-1/PD-L1 interaction with an IC50 of 39.2 nM. It contains the target protein PD-1/PD-L1 ligand and PROTAC linker, which can be used to synthesize PROTAC PD-1/PD-L1 degrader-1 and has anticancer activity. Additionally, it serves as a diluent for the preparation of tablets for direct compression.

BMS-199264 hydrochloride is the salt form of BMS-199264.BMS-199264 is a potent and selective inhibitor of mitochondrial F1F0 ATP hydrolase with an IC50=0.5 μM.BMS-199264 is able to inhibit the decline of ATP during myocardial ischemia, reduce myocardial necrosis, and enhance the recovery of myocardial contractile function after reperfusion.

BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. BMS-1001 is capable of alleviating the PD-1/PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes.

Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM). BMS-1166 hydrochloride is an inhibitor of PD-1/PD-L1 interaction (IC50: 1.4 nM). BMS-1166 rivalries the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.

BMS-196085 is an effective and selective human β( 3) All agonists of adrenergic receptors, in β( 1) Partial agonist activity was 45%.

BMS-1166-N-piperidine-COOH is a chemical compound that functions as the BMS-1166-based moiety. It binds to the E3 ligase ligand through a linker, leading to the formation of PROTAC PD-1/PD-L1 degrader-1, which facilitates the degradation of PD-1/PD-L1. BMS-1166 demonstrates potent inhibition of PD-1/PD-L1 interaction, with an IC 50 of 1.4 nM. By antagonizing the inhibitory effect of the PD-1/PD-L1 immune checkpoint on T cell activation, BMS-1166 promotes T cell activation.

BMS-1166-N-piperidine-CO-N-piperazine is a chemical compound containing a PD-1/PD-L1 immune checkpoint ligand and a PROTAC linker. It is used in synthesizing [PROTAC PD-1/PD-L1 degrader-1], which effectively inhibits the PD-1/PD-L1 interaction with an IC50 value of 39.2 nM.

BMS-1166 is a potent inhibitor of the PD-1/PD-L1 interaction.

BMS-191011 (BMS-A) is an activator of large-conductance calcium-activated potassium (BKCa) channels ,effective in stroke models

BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).

BMS-1233 is an orally effective programmed death ligand 1 (PD-L1) inhibitor with an IC50 of 14.5 nM. This compound promotes the death of HepG2 cells in a co-culture model with Jurkat T cells and exhibits antitumor activity against melanoma in mouse models.

BMS-191095 is mitochondrial ATP-sensitive potassium (mitoKATP) channel activator.

BMS-193885 is a selective, brain-penetrant, and competitive antagonist of the neuropeptide Y1 receptor with a Ki of 3.3 nM, and an IC50 of 5.9 nM for hY1.

BMS-191095 hydrochloride is a mitochondrial KATP channel opener. It offers cardioprotective benefits without causing vasodilation or impacting electrophysiology. Its protective mechanisms include prolonging myocardial contraction during ischemia, enhancing contractile function post-reperfusion, and reducing lactate dehydrogenase (LDH) release.

BMS-185354 is a selective RARγ activator with an EC50 value of 28 nM, offering potential for cancer research.

BMS-180431 sodium is an HMG-CoA reductase inhibitor with an IC50 of 43 nM.

BMS-135 is a potent and selective ATP-competitive inhibitor of casein kinase 2 (CK2), with IC50 values of 0.8 nM for CK2α and 0.3 nM for CK2α' isoforms. It mimics the structure of ATP, binding to the active site of CK2 and inhibiting its serine/threonine phosphorylating activity. BMS-135 effectively inhibits cell proliferation and demonstrates antitumor properties, making it useful for research in colon cancer.

BMS-159 is an orally active prodrug of BMS-135, a potent ATP-competitive CK2 inhibitor. BMS-159 is utilized in research related to neurological disorders and cancer.

BMS-189664 is an inhibitor of thrombin.

BMS-189664 HCl is a selective and orally active thrombin active site inhibitor.

BMS-199945 is an Influenza H1N1 Virus inhibitor.

BMS-180492 is a bio-active chemical.

BMS-185411 is a bio-active chemical.